PF-Atlas › Clinical Trials › NCT07080125
A Study Using a Disease Registry to Observe the Long-term Effects of Nintedanib in People With Scleroderma-related Lung Fibrosis
Ofev® · Not specified
Registry ID
NCT07080125
Phase
Not specified
Status
Active, not recruiting
Drug / intervention
Ofev®
Sponsor
Boehringer Ingelheim
Start
2025-06-17
Enrollment
2000
Locations
1
About this trial
This post-approval registry study is planned to generate data to address remaining questions on long-term effectiveness and to better characterize longer term beneficial effects of Nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) in terms of survival, quality of life, pattern of disease progression as well as effectiveness and safety in the subgroup of patients with pulmonary hypertension.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT07080125 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.